GGrantIndex
← Leaderboards

Christian Capitini

University Of Wisconsin-Madison

$4,273,809
Attributed
$6,560,968
Total exposure
5
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $6.3M · FY201425
$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,041,936 · 6

By mechanism

P30$10,669,303 · 2
R01$5,657,673 · 3
K08$714,960 · 1

Top collaborators

Most similar at University Of Wisconsin-Madison

Same institution · by research overlap

Others in their field

Top investigators on “In Vivo

Research focus

In VivoResponseHigh RiskNovel TherapeuticsAllogenicMediatingLabelInfusion ProceduresMouse ModelTumorLeadProductionCytokineCellsSignal TransductionRadiationResearch PriorityImmunologicsInnovationHematopoietic Stem CellsTranslationsSolid NeoplasmPathway InteractionsCancer Cell

Grant awards (20)

UW Comprehensive Cancer Center Support$5,240,484
P30 · FY2025 · CA · contact PI
Label-free imaging of CAR T cell metabolism$647,057
R01 · FY2025 · CA
UW Comprehensive Cancer Center Support$5,240,484
P30 · FY2024 · CA · contact PI
Label-free imaging of CAR T cell metabolism$615,789
R01 · FY2024 · CA
Exosome educated monocytes for acute radiation syndrome$432,060
R01 · FY2024 · HL · contact PI
Label-free imaging of CAR T cell metabolism$662,022
R01 · FY2023 · CA
Exosome educated monocytes for acute radiation syndrome$525,256
R01 · FY2023 · HL · contact PI
Exosome educated monocytes for acute radiation syndrome$525,256
R01 · FY2022 · HL · contact PI
Combining hu14.18-IL2 and NK cell infusions to treat neuroblastoma$347,078
R01 · FY2022 · CA · contact PI
Developmental Therapeutics Research Program$84,939
P30 · FY2022 · CA · contact PI
Exosome educated monocytes for acute radiation syndrome$525,256
R01 · FY2021 · HL · contact PI
Combining hu14.18-IL2 and NK cell infusions to treat neuroblastoma$347,078
R01 · FY2021 · CA · contact PI
Developmental Therapeutics Research Program$103,396
P30 · FY2021 · CA · contact PI
Combining hu14.18-IL2 and NK cell infusions to treat neuroblastoma$347,078
R01 · FY2020 · CA · contact PI
Combining hu14.18-IL2 and NK cell infusions to treat neuroblastoma$336,665
R01 · FY2019 · CA · contact PI
Combining hu14.18-IL2 and NK cell infusions to treat neuroblastoma$347,078
R01 · FY2018 · CA · contact PI
Inhibiting STAT1 as a novel graft-versus-host/graft-versus-leukemia therapy$178,740
K08 · FY2017 · CA · contact PI
Inhibiting STAT1 as a novel graft-versus-host/graft-versus-leukemia therapy$178,740
K08 · FY2016 · CA · contact PI
Inhibiting STAT1 as a novel graft-versus-host/graft-versus-leukemia therapy$178,740
K08 · FY2015 · CA · contact PI
Inhibiting STAT1 as a novel graft-versus-host/graft-versus-leukemia therapy$178,740
K08 · FY2014 · CA · contact PI